Todas las investigaciones
ReclutamientoFASE3INTERVENCIONISTA

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

This study is looking into a new medicine called efgartigimod for adults who have a blood condition called primary immune thrombocytopenia (ITP). ITP causes low levels of platelets, which are important for blood clotting. The main goal is to find out how well efgartigimod works (its 'efficacy') and if it's safe to use. You'd first have a check-up period, then be randomly assigned to receive either the study drug (efgartigimod) or a dummy treatment (placebo) for up to 24 weeks. After this, everyone will receive efgartigimod for about two years, followed by a period where no study drug is given. The whole study could last up to 138 weeks.

De un vistazo

Estado
Reclutamiento
Fase
FASE3
Patrocinador
argenx
Objetivo de inscripción
69
Inicio
18 Oct 2024
Estimación de finalización
01 Jun 2028

¿De qué trata este estudio?

This study is designed to learn more about a new treatment, efgartigimod, for adults living with primary immune thrombocytopenia, often just called ITP. ITP is a condition where your body's immune system mistakenly attacks and destroys its own platelets, which are tiny cells in your blood that help it clot. If you don't have enough platelets, you can bruise easily or bleed more than usual.

The researchers want to see if efgartigimod can help increase platelet counts and reduce bleeding in people with ITP. They also want to understand if the medicine is safe and doesn't cause too many side effects. Comparing it to a placebo (a treatment that looks like the real thing but has no active medicine) helps them truly see the effect of efgartigimod.

Participating could mean you receive a new treatment that might help your ITP, or you might receive a placebo at first. After a certain period, everyone in the study will get the active medicine. This type of research is really important because it helps doctors find better ways to manage conditions like ITP and improve the lives of people living with them.

Puntos clave

  • This study is testing a new medicine for adults with ITP.
  • It aims to see how well efgartigimod works and if it's safe.
  • Participation involves receiving either the study drug or a placebo at first.
  • Everyone on the study will get the active medicine eventually.
  • The study involves regular clinic visits for IV treatments and check-ups.
  • The total study duration could be up to 2.5 years.

¿Quién puede ser elegible?

To join this study, you need to be at least 18 years old. You must also have had primary ITP for more than a year and have a low platelet count. In the past, you should have tried at least one common ITP treatment (like steroids, IVIg, or other specific medicines) and it didn't work well enough.

There are also some reasons why you might not be able to join. For instance, if you have other serious health problems or a different type of ITP (not primary ITP), or if you have certain related conditions like another serious autoimmune disease or a current severe bleeding problem, you wouldn't be able to take part.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes al menos 18 años?
  2. Have you had primary ITP for more than one year?
  3. Do you currently have a low platelet count (less than 30)?
  4. Have you tried at least one previous ITP treatment (like steroids or IVIg) and it didn't work well enough?
  5. Have you had at least one platelet count of 50 or higher in response to a past ITP treatment (like prednisone, IVIg, etc.) in the last three years?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you'll first have a screening period of up to two weeks to make sure the study is right for you. If you qualify, you'll be randomly assigned to one of two groups: either you'll receive efgartigimod, or you'll receive a placebo (a dummy medicine). You won't know which one you're getting, and neither will your study doctor, during this 'double-blind' period, which lasts up to 24 weeks.

After this initial phase, everyone will then receive efgartigimod for about 52 weeks. If you and your doctor agree, you might continue receiving efgartigimod for another 52 weeks. Throughout the study, you'll have regular visits to the clinic for check-ups, blood tests, and to receive your study medication, which will be given as an IV (into a vein). After all the treatment periods, there will be a follow-up period of about eight weeks where you won't be taking the study drug. The total time you'd be involved in the study could be up to 138 weeks (roughly 2.5 years).

Riesgos y beneficios potenciales

Taking part in a clinical trial offers potential benefits, such as receiving close medical care and access to a new treatment before it's widely available. However, there are also potential risks, including side effects from the study medication or the possibility that the treatment may not work for you. As with any medical procedure, there could be discomfort from blood tests or IV injections. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care, and this will be fully explained before you agree to take part.

Locations (94)

  • Mayo Clinic Hospital Scottsdale
    Código postal verificado
    Phoenix, Estados Unidos· Reclutamiento
  • University of Southern California Norris Comprehensive Cancer Center
    Código postal verificado
    Los Angeles, United States· Reclutamiento
  • Sharp Memorial Hospital
    Código postal verificado
    Oceanside, United States· Reclutamiento
  • University of Colorado Hospital
    Código postal verificado
    Aurora, Estados Unidos· Reclutamiento
  • Yale University School of Medicine
    Código postal verificado
    New Haven, Estados Unidos· Reclutamiento
  • Georgetown University Hospital
    Código postal verificado
    Washington D.C., Estados Unidos· Reclutamiento
  • The University of Chicago Medicine
    Código postal verificado
    Chicago, Estados Unidos· Reclutamiento
  • The University of Iowa Hospitals & Clinics
    Código postal verificado
    Iowa City, Estados Unidos· Reclutamiento
  • Tulane University
    Código postal verificado
    New Orleans, United States· Reclutamiento
  • Henry Ford Health
    Código postal verificado
    Detroit, Estados Unidos· Reclutamiento
  • University of Minnesota
    Código postal verificado
    Minneapolis, United States· Reclutamiento
  • Regional Cancer Care Associates, LLC (RCCA)
    Código postal verificado
    Little Silver, United States· Reclutamiento

Preguntas comunes

What is primary immune thrombocytopenia (ITP)?

ITP is a blood disorder where your immune system attacks and destroys your own platelets, which are essential for blood clotting. This can lead to easy bruising or bleeding.

What is efgartigimod?

Efgartigimod is the new experimental medicine being tested in this study to see if it can help increase platelet counts in people with ITP.

¿Qué es un 'placebo'?

A placebo is a treatment that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers understand the true effect of the active medication.

¿Cómo se administrará el medicamento?

The study medicine, efgartigimod (or the placebo), will be given as an intravenous (IV) infusion, meaning it will be delivered directly into a vein.

¿Cuánto tiempo estaré en el estudio?

The study could last for up to 138 weeks, which is about two and a half years, including treatment and follow-up periods.

Cómo obtener más información

Sabine Coppieters, MD

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Study to Assess the Efficacy and Safety of Efgartigimod IV…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.